• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

紫杉醇和帕博利珠单抗在铂类难治性上皮性卵巢癌伴广泛血栓栓塞病例中的超说明书用药

Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism.

作者信息

Lam Clarissa, Ha Kristal, Hakam Ardeshir, Shahzad Mian M K

机构信息

Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, USA.

Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.

出版信息

Gynecol Oncol Rep. 2022 May 2;41:100992. doi: 10.1016/j.gore.2022.100992. eCollection 2022 Jun.

DOI:10.1016/j.gore.2022.100992
PMID:35540026
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9079239/
Abstract

•Management of platinum refractory ovarian cancer is challenging.•Extensive venous thromboembolism precludes anti-angiogenic combination chemotherapy.•Weekly paclitaxel and immune-checkpoint inhibitor combination provides a durable tumor control option.

摘要

•铂耐药卵巢癌的管理具有挑战性。

•广泛的静脉血栓栓塞排除了抗血管生成联合化疗。

•每周紫杉醇与免疫检查点抑制剂联合提供了一种持久的肿瘤控制选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671e/9079239/e1bb707fb39b/gr2c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671e/9079239/007366ef222b/gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671e/9079239/ed2888da1ff5/gr2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671e/9079239/0708c9526190/gr2b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671e/9079239/e1bb707fb39b/gr2c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671e/9079239/007366ef222b/gr1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671e/9079239/ed2888da1ff5/gr2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671e/9079239/0708c9526190/gr2b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/671e/9079239/e1bb707fb39b/gr2c.jpg

相似文献

1
Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism.紫杉醇和帕博利珠单抗在铂类难治性上皮性卵巢癌伴广泛血栓栓塞病例中的超说明书用药
Gynecol Oncol Rep. 2022 May 2;41:100992. doi: 10.1016/j.gore.2022.100992. eCollection 2022 Jun.
2
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.帕唑帕尼联合每周紫杉醇与单独每周紫杉醇治疗铂耐药或铂难治性晚期卵巢癌（MITO 11）：一项随机、开放标签、2 期试验。
Lancet Oncol. 2015 May;16(5):561-8. doi: 10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14.
3
Optimal chemotherapy treatment for women with recurrent ovarian cancer.复发性卵巢癌女性的最佳化疗治疗。
Curr Oncol. 2007 Oct;14(5):195-208. doi: 10.3747/co.2007.148.
4
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.奥法利纳单抗（VB-111）治疗铂耐药卵巢癌；I/II 期研究中观察到的缓解率与免疫治疗作用相关。
Gynecol Oncol. 2020 Jun;157(3):578-584. doi: 10.1016/j.ygyno.2020.02.034. Epub 2020 Apr 5.
5
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.评估间歇性和连续性依维莫司与每周紫杉醇在铂类耐药复发性卵巢上皮癌患者中的 2 期研究。
Gynecol Oncol. 2018 May;149(2):275-282. doi: 10.1016/j.ygyno.2018.01.019. Epub 2018 Feb 14.
6
Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.拓扑替康、聚乙二醇化脂质体盐酸多柔比星和紫杉醇用于晚期卵巢癌二线或后续治疗：一项系统评价和经济学评估
Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090.
7
Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.一线免疫检查点抑制剂与医疗保险覆盖的晚期非小细胞肺癌患者生存的关联。
JAMA Netw Open. 2021 May 3;4(5):e2111113. doi: 10.1001/jamanetworkopen.2021.11113.
8
Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.联合顺铂或紫杉醇治疗铂类/紫杉烷类耐药/难治性上皮性卵巢癌、输卵管癌或原发性腹膜癌的苯氧二醇的 II 期评价。
Int J Gynecol Cancer. 2011 May;21(4):633-9. doi: 10.1097/IGC.0b013e3182126f05.
9
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.派姆单抗联合白蛋白紫杉醇作为铂类治疗后局部晚期或转移性尿路上皮癌的挽救疗法：开放标签、单臂、Ⅱ期 PEANUT 研究的中期结果。
Ann Oncol. 2020 Dec;31(12):1764-1772. doi: 10.1016/j.annonc.2020.09.012. Epub 2020 Sep 23.
10
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.阿维鲁单抗单药或联合化疗对比单纯化疗用于铂耐药或铂难治性卵巢癌（JAVELIN Ovarian 200）：一项开放标签、三臂、随机、3期研究。
Lancet Oncol. 2021 Jul;22(7):1034-1046. doi: 10.1016/S1470-2045(21)00216-3. Epub 2021 Jun 15.

引用本文的文献

1
Association of a CHEK2 somatic variant with tumor microenvironment calprotectin expression predicts platinum resistance in a small cohort of ovarian carcinoma.CHEK2体细胞变异与肿瘤微环境钙卫蛋白表达的关联可预测一小群卵巢癌患者对铂类药物的耐药性。
PLoS One. 2025 Mar 27;20(3):e0315487. doi: 10.1371/journal.pone.0315487. eCollection 2025.
2
Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study.白蛋白紫杉醇联合铂类作为卵巢癌一线化疗的有效性和安全性：一项回顾性研究。
J Gynecol Oncol. 2023 Jul;34(4):e44. doi: 10.3802/jgo.2023.34.e44. Epub 2023 Feb 6.
3

本文引用的文献

1
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.帕博利珠单抗联合贝伐珠单抗和口服环磷酰胺节拍化疗治疗复发性卵巢癌的疗效和安全性：一项 2 期非随机临床试验。
JAMA Oncol. 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945.
2
Responses of metastatic primary fallopian tube carcinoma to pembrolizumab and nab-paclitaxel: A case report.转移性原发性输卵管癌对帕博利珠单抗和白蛋白结合型紫杉醇的反应：一例报告
Medicine (Baltimore). 2020 Jul 10;99(28):e21203. doi: 10.1097/MD.0000000000021203.
3
Mismatch repair deficiency in ovarian cancer.
卵巢癌中的错配修复缺陷
Gynecol Oncol Rep. 2022 May 30;41:101015. doi: 10.1016/j.gore.2022.101015. eCollection 2022 Jun.
Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors.
接受免疫检查点抑制剂治疗的癌症相关血栓形成患者的风险因素。
Invest New Drugs. 2020 Aug;38(4):1200-1206. doi: 10.1007/s10637-019-00881-6. Epub 2019 Dec 10.
4
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.帕博利珠单抗联合紫杉醇治疗复发或难治性小细胞肺癌的 II 期研究。
Lung Cancer. 2019 Oct;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. Epub 2019 Aug 29.
5
Progress in research on paclitaxel and tumor immunotherapy.紫杉醇与肿瘤免疫治疗研究进展。
Cell Mol Biol Lett. 2019 Jun 13;24:40. doi: 10.1186/s11658-019-0164-y. eCollection 2019.
6
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.帕博利珠单抗治疗晚期复发性卵巢癌患者的抗肿瘤活性和安全性：来自 II 期 KEYNOTE-100 研究的结果。
Ann Oncol. 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135.
7
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.派姆单抗治疗程序性死亡配体 1 阳性晚期卵巢癌患者：KEYNOTE-028 分析。
Gynecol Oncol. 2019 Feb;152(2):243-250. doi: 10.1016/j.ygyno.2018.11.017. Epub 2018 Dec 3.
8
Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells.铂类和紫杉烷类化疗药物治疗卵巢癌对正常细胞生物学的影响的综合综述。
Cell Mol Life Sci. 2019 Feb;76(4):681-697. doi: 10.1007/s00018-018-2954-1. Epub 2018 Oct 31.
9
Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.帕博利珠单抗：PD -1抑制作为癌症治疗策略
Drugs Today (Barc). 2015 Jan;51(1):7-20. doi: 10.1358/dot.2015.51.1.2250387.
10
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.贝伐珠单抗联合化疗治疗铂耐药复发性卵巢癌：AURELIA 开放性随机 III 期试验。
J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17.